Kawashima Jun, Akabane Miho, Woldesenbet Selamawit, Tsilimigras Diamantis I, Endo Yutaka, Sahara Kota, Cauchy François, Aucejo Federico, Marques Hugo P, Lopes Rita, Rodriguea Andreia, Hugh Tom, Shen Feng, Maithel Shishir K, Groot Koerkamp Bas, Popescu Irinel, Kitago Minoru, Weiss Matthew J, Martel Guillaume, Pulitano Carlo, Aldrighetti Luca, Poultsides George, Ruzzente Andrea, Bauer Todd W, Gleisner Ana, Endo Itaru, Pawlik Timothy M
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.
Ann Surg Oncol. 2025 Jul 9. doi: 10.1245/s10434-025-17776-x.
Recent advancements in systemic chemotherapy have fueled debates regarding the feasibility of combining systemic therapy with surgery for advanced intrahepatic cholangiocarcinoma (ICC). However, the absence of consensus on oncological resectability criteria has hindered discussions on optimal multidisciplinary management. This study sought to propose preoperative oncological resectability criteria for ICC.
Patients undergoing upfront curative-intent hepatectomy for ICC were identified from an international multi-institutional database. Independent tumor-related prognostic factors for overall survival were identified by using multivariable Cox regression and utilized to develop resectability criteria.
Among 953 patients, four independent tumor-related predictors of poor prognosis were identified: lymph node metastasis (LNM) on imaging (HR 1.3, 95% confidence interval [CI] 1.07-1.59), tumor size > 5 cm (hazard ratio [HR] 1.52, 95% CI 1.25-1.85), multinodular lesions (HR 2.03, 95% CI 1.64-2.52), and major vascular invasion (HR 1.64, 95% CI 1.34-2.01). High-risk points were identified based on a point system associated with the hazards of each factor: 1 point each for LNM, tumor size > 5 cm, and major vascular invasion, and 2 points for multinodular lesions. Patients were categorized as resectable (R) for scores of 0-1 or borderline resectable (BR) for scores ≥ 2. Patients with BR disease (n = 385, 40.4%) had markedly worse median overall survival versus individuals with R disease (n = 568, 59.6%) (24.6 months vs. 69.7 months, p < 0.001). Validation in an external cohort confirmed these findings.
The proposed preoperatively assessable resectability criteria can help differentiate BR versus R disease among ICC patients. These criteria offer a practical framework for preoperative risk stratification, aiding in treatment planning.
全身化疗的最新进展引发了关于晚期肝内胆管癌(ICC)全身治疗与手术联合应用可行性的讨论。然而,肿瘤可切除性标准缺乏共识阻碍了关于最佳多学科管理的讨论。本研究旨在提出ICC的术前肿瘤可切除性标准。
从国际多机构数据库中识别接受根治性意向肝切除术治疗ICC的患者。通过多变量Cox回归确定总生存的独立肿瘤相关预后因素,并用于制定可切除性标准。
在953例患者中,确定了四个独立的肿瘤相关预后不良预测因素:影像学检查发现淋巴结转移(LNM)(风险比[HR]1.3,95%置信区间[CI]1.07 - 1.59)、肿瘤大小>5 cm(HR 1.52,95% CI 1.25 - 1.85)、多结节病变(HR 2.03,95% CI 1.64 - 2.52)和主要血管侵犯(HR 1.64,95% CI 1.34 - 2.01)。根据与各因素风险相关的评分系统确定高危点:LNM、肿瘤大小>5 cm和主要血管侵犯各为1分,多结节病变为2分。评分为0 - 1分的患者被归类为可切除(R),评分≥2分的患者被归类为边界可切除(BR)。BR疾病患者(n = 385,40.4%)的中位总生存期明显低于R疾病患者(n = 568,59.6%)(24.6个月对69.7个月,p < 0.001)。外部队列的验证证实了这些发现。
所提出的术前可评估的可切除性标准有助于区分ICC患者中的BR与R疾病。这些标准为术前风险分层提供了一个实用框架,有助于治疗规划。